Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in primary outcome: complete clinical response compared with oral chloroquine (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Treatment responsea · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained clinically inactive diseasec · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review